Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancerDavid D.L. Bowtell, Frances R. Balkwill, Usha Menon et al.|Nature reviews. Cancer|2015Cited by 1.4k
<i>BRCA</i> Mutation Frequency and Patterns of Treatment Response in <i>BRCA</i> Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study GroupKathryn Alsop, Gillian Mitchell, Sián Fereday et al.|Journal of Clinical Oncology|2012Cited by 1.2k
Prognostically relevant gene signatures of high-grade serous ovarian carcinomaRoel G.W. Verhaak, Matthew Meyerson, Pablo Tamayo et al.|Journal of Clinical Investigation|2012Cited by 591
ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cellsStephanie A. Yazinski, Lee Zou, Valentine Comaills et al.|Genes & Development|2017Cited by 398
Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse epidermal cells.Zigang Dong, Nancy H. Colburn, Michael J. Birrer et al.|Proceedings of the National Academy of Sciences|1994Cited by 388